Physician profile
David Wayne Rouse
NPI 1720047574
$6,933.98
in general payments reported to CMS, 2019-2025
21 companies · $921 in 2025
The $921 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $121 · 2021: $990 · 2022: $3,535 · 2023: $481 · 2024: $658 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Entertainment: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.16 |
| Entertainment | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,767.00 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $744.73 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Coopervision INC. | $456.73 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $247.93 | 2022-2025 | Miebo, Xiidra, Infuse |
| Biotissue Holdings INC. | $181.33 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $178.85 | 2024-2025 | Xdemvy |
| Optos, INC. | $158.74 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $157.14 | 2020-2022 | |
| Allergan, INC. | $154.76 | 2020-2021 | |
| Abbvie INC. | $154.21 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $145.26 | 2022 | |
| Kala Pharmaceuticals, INC. | $121.43 | 2021 | |
| Sun Pharmaceutical Industries INC. | $117.22 | 2021-2023 | Cequa |
| Oyster Point Pharma, INC. | $98.08 | 2023-2024 | Tyrvaya |
| Topcon Healthcare, INC. | $75.46 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $42.08 | 2023-2024 | Iyuzeh |
| Visionix USA, INC | $41.66 | 2022 | |
| Glaukos Corporation | $36.64 | 2025 | Photrexa Viscous and Photrexa |
| Maculogix, INC. | $36.04 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.20 | 2021 | |
| Abb Con-Cise Optical Group LLC | $4.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.